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Background: The aim of the study was to evaluate the efficacy and safety of ziprasidone versus 
risperidone in Chinese subjects with acute exacerbation of schizophrenia.
Methods: In patients meeting the Chinese Classification of Mental Disorders criteria for 
schizophrenia and with a Positive and Negative Syndrome Scale (PANSS) total score $60 
were randomly assigned to six weeks of double-blind treatment with ziprasidone 40–80 mg 
twice daily or risperidone 1–3 mg bid, flexibly dosed. Noninferiority was demonstrated if the 
upper limit of the two-sided 95% confidence interval (CI) for the difference in PANSS total 
score improvement from baseline in the evaluable population was smaller than the prespecified 
noninferiority margin of 10 units.
Results: The intent-to-treat population comprised 118 ziprasidone-treated and 121 risperidone-
treated subjects. Improvement (reduction) from baseline to week 6 in PANSS total score 
was (−35.6 [95% CI: −38.6, −32.6]) for ziprasidone and (−37.1 [95% CI: −39.9, −34.4]) for 
risperidone. Noninferiority was demonstrated in the evaluable population with a difference 
score of 1.5 [95% CI: −2.5, 5.5]. Mean prolactin levels decreased at week 6 compared with 
baseline for ziprasidone (−3.5 ng/mL), but significantly increased for risperidone (61.1 ng/mL; 
P , 0.001). More risperidone-treated subjects (14.9%) than ziprasidone-treated subjects (4.2%) 
reported weight gain $7%. Akathisia and somnolence in the ziprasidone group and akathisia 
and insomnia in the risperidone group were the most common side effects. Treatment-related/
treatment-emergent adverse events were reported by 79.7% and 71.1% of ziprasidone-treated 
and risperidone-treated subjects, respectively.
Conclusion: In Chinese subjects, ziprasidone was as effective as risperidone, with less weight 
gain and less prolactin elevation.
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Introduction
Ziprasidone is a potent antagonist at 5-hydroxytriptamine (serotonin) 5-HT2A and 
dopamine D2 receptors, and has the highest ratio of affinities at these receptors among 
the available antipsychotic agents.1 In addition, ziprasidone is a potent 5-HT1A agonist, a 
potent 5-HT1D and 5-HT2C antagonist, and moderately inhibits 5-HT and noradrenaline 
reuptake sites in vitro. This unique collection of properties, in addition to its antipsychotic 
efficacy, may offer considerable potential benefits in treatment of the affective symptoms 
associated with schizophrenia, and also predicts a low propensity for extrapyramidal 
symptoms, sedation, and cognitive impairment.1 Ziprasidone has demonstrated a low 
propensity for drug interactions during in vitro and in vivo studies.
Several 4–6-week, fixed-dose (40–200 mg/day), placebo-controlled clinical trials 
in subjects with schizophrenia and schizoaffective disorder have demonstrated that Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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ziprasidone is an effective antipsychotic agent for positive, 
negative, and affective symptomatology associated with 
schizophrenia.2–4 The incidence and severity of adverse 
events associated with ziprasidone has been low. Ziprasidone 
demonstrates a relatively low incidence of extrapyramidal 
symptoms, and the incidence of postural hypotension and 
laboratory abnormalities has been found to be similar to 
that observed with placebo.2–4 A recent large, multinational, 
observational study comparing ziprasidone and olanzapine 
determined that, despite the known risk of QTc prolongation 
for ziprasidone, it was not associated with an elevated risk 
for nonsuicide-related (specifically cardiac) adverse events 
in real world use.5
Among the most extensively studied and widely used 
atypical agents, risperidone has been studied in patients with 
schizophrenia in comparison with haloperidol.6–10 Although 
risperidone has demonstrated efficacy in the treatment of 
schizophrenia, several studies have revealed that treatment 
with risperidone is accompanied by some tolerability 
problems, including extrapyramidal symptoms, serum 
prolactin elevation, and sexual dysfunction.11,12
The present study compared the efficacy, safety, and 
tolerability profiles of ziprasidone and risperidone in treating 
schizophrenia in Chinese subjects. It is among the first 
double-blind studies to compare two different atypical 
antipsychotic agents in Chinese subjects with schizophrenia. 
There have been few randomized, controlled clinical studies 
of atypical antipsychotics in Asian populations, and they 
have several important factors that vary between different 
racial and ethnic groups.13,14 Some studies have demonstrated 
differences in efficacious doses of antipsychotics, as well as 
antipsychotic response, among different racial and ethnic 
groups.13,15,16 However, some other studies have failed to 
replicate these findings.17,18 Hence, the additional aim of this 
study was to document differences, if any, in average dose, 
clinical response, and safety profile of ziprasidone between 
Chinese and Western populations.
Methods
subjects
The trial included male and female inpatients aged 
18–65 years. At randomization, subjects with a diagnosis 
of schizophrenia according to the Chinese Classification of 
Mental Disorders (CCMD-3) criteria were hospitalized, and 
were required to have a Positive and Negative Syndrome 
Scale (PANSS) score $60.19 Written informed consent was 
obtained from all subjects. Exclusion criteria included a 
CCMD-3-defined diagnosis of substance abuse within the 
three months prior to randomization or any of the following 
prior to randomization: intermittent (within 12 hours) use 
or planned regular use (within one week) of antipsychotic 
agents, depot agents (the longer of two weeks or one cycle), 
treatment with antidepressants (one week, except two weeks 
for monoamine oxidase inhibitors including meclobemide and 
five weeks for fluoxetine), mood stabilizers (one week), regular 
administration of clozapine (within three months), or regular 
administration of risperidone (within four weeks). Exclusion 
criteria also included receiving another investigational agent 
one month prior to screening, termination of risperidone due 
to nonresponse or intolerability, resistance to conventional 
antipsychotics, at immediate risk of the impulse to commit 
harm to self or others, QTc prolongation or a predrug QTc 
of $450 msec, pregnant or lactating women, or women of 
childbearing potential not using an acceptable method of 
contraception, confirmed clinically significant abnormal 
laboratory values and/or electrocardiogram as determined 
by a general physician or cardiologist.
study design
This was a randomized, double-blind, double-dummy, active-
controlled, parallel-group, multicenter study. The Chinese 
State Food and Drug Administration required that a minimum 
of 100 pairs of subjects complete the study. Therefore, this 
study aimed to enroll 240 subjects. The additional subject 
numbers allowed for approximately 17% nonevaluability. 
At baseline, subjects received double-dummy study drug 
(ziprasidone capsules or risperidone capsules, and matching 
placebo). Subjects received all study drugs with food and 
under supervision. During the first week, the dose was 
steadily titrated upwards for all subjects (see Table 1 for 
dosing regimen). At the end of week 1, the dosage was 
titrated up or down, based on the clinical status of the 
subject and the safety and tolerability of the study drug. Any 
medication taken, other than the study drug, was considered 
to be concomitant medication. All concomitant medications 
taken during the three months prior to screening and during 
the course of the study were recorded. Specifically, standard 
anticholinergics were permitted when deemed necessary, 
but not prophylactically, while benzodiazepines could be 
administered parenterally for the first three days of the 
Table 1 study drug regimen
Day/week Ziprasidone, mg/daya Risperidone, mg/dayb
Day 1–2 80 1
Day 3–4 120 2
Day 5–7 120 3
Week 2–6 80, 120, or 160  2, 4, or 6
Notes: aZiprasidone was dosed twice daily; brisperidone was dosed once daily for 
the first seven days, then twice daily thereafter.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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study (clonazepam up to 4 mg or surazepam up to 2 mg per 
night). Standard procedures were used to ensure rater training 
and reliability during the investigation. A double-dummy 
method was used to keep both subjects and investigators 
blinded to the treatment allocation. A computer-generated 
randomization schedule was used to randomize subjects to 
either ziprasidone or risperidone, and was accessed by the 
investigators via an interactive voice response system each 
time a eligible subject was available for randomization.
The study was conducted in compliance with the 
Declaration of Helsinki and the International Electrotechnical 
Commission, informed consent regulations, and International 
Conference on Harmonization, and Good Clinical Practices 
guidelines. In addition, all local regulatory requirements were 
followed, in particular, those affording greater protection to 
the safety of trial participants.
Evaluation of efficacy and safety
The primary efficacy evaluation was the PANSS total score. 
Secondary efficacy evaluations included the Brief Psychiatric 
Rating Scale (BPRSd [derived from 18 PANSS items]), PANSS 
subscales (positive, negative, general psychopathology) and 
responder rate (defined as $50% reduction from baseline 
PANSS total score), and Clinical Global Impression-Severity 
(CGI-S) and CGI-Improvement (CGI-I) scales.
All observed or self-reported adverse events, regardless of 
treatment group or suspected causal relationship to the study 
drugs, were recorded. The severity, duration, and possible 
relationship to the study drugs of all adverse events were 
also recorded. Laboratory tests, performed at screening and 
the end of treatment, included aspartate aminotransferase, 
alanine aminotransferase, alkaline phosphatase, blood 
glucose (eight-hour fasting), and serum prolactin. The 
rating scale for extrapyramidal side effects (known as the 
Simpson–Angus scale), and Barnes Akathisia scale were also 
measured.20 Physical examination findings, vital signs, and 
electrocardiographic parameters, including QTc intervals 
(using the Bazett correction), were recorded.
statistical analysis
This study included a safety population and two efficacy 
analysis populations, ie, the intent-to-treat population and the 
evaluable population. All efficacy variables were analyzed 
using the intent-to-treat population. Only the primary 
measure was analyzed using the evaluable population. 
The intent-to-treat population was defined as any subject who 
took at least one dose of study medication and had a baseline 
and a follow-up (postbaseline) efficacy measurement. 
The evaluable population was a subset of the intent-to-treat 
population, and comprised subjects with a baseline and end 
of study (week 6) PANSS total score, no major protocol 
deviations, and compliance with study medication (.70% 
or ,120%). The safety population consisted of all subjects 
who took at least one dose of study medication.
Detailed descriptive summaries of efficacy and safety 
outcomes are tabulated, along with summaries of adverse 
events, treatment discontinuations, vital signs, laboratory 
assessments, electrocardiographic parameters, physical 
examinations, concomitant medications, and treatments for 
the safety population.
All tests of hypotheses were two-sided and conducted 
at the 5% significance level without adjustment for mul-
tiple comparisons, and all confidence intervals (CIs) were 
two-sided at the 95% level or suitable data transformations 
applied, and nonparametric methods were used. If the 
response at end of study was missing for the primary efficacy 
endpoint (intent-to-treat population analysis), secondary 
efficacy or safety endpoints (Simpson–Angus scale and 
Barnes Akathisia scale), or the last available postbaseline 
observation was carried forward (LOCF).
The primary endpoint was change in the PANSS total 
score from baseline to study end. Assuming a two-sided 
significance level of 5%, the same underlying mean change 
from baseline in PANSS total score for the two treatments, 
a common standard deviation (SD) of 25 units, and a 
nonevaluability rate of 17%, a sample size of 240 subjects 
allowed for the noninferiority of ziprasidone compared with 
risperidone to be established within 10 units (noninferiority 
margin) with 80% power.
Change in PANSS positive subscale score from baseline 
to end of study, change in PANSS negative subscale score 
from baseline to end of study, change in PANSS general 
psychopathology score from baseline to end of study, and 
change in BPRSd score from baseline to end of study 
were analyzed using an analysis of covariance (ANCOVA) 
model with treatment group and study center as factors, and 
the baseline score as a covariate. The least squares mean, 
standard error, 95% CI for the mean difference, and P value 
were presented for all endpoints analyzed using ANCOVA. 
Responder rate, as derived from the reduction from baseline 
in the PANSS total score at end of study, was analyzed using 
the Cochran–Mantel–Haenszel test stratified by study center. 
An estimate of the overall odds ratio (stratified by study 
center) and its associated 95% CI were also presented.
CGI-S and CGI-I scores at end of study were analyzed 
using Wilcoxon rank-sum tests stratified by study center. 
Assessment of the difference between the treatment groups 
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score #2 versus .2 at the end of study was also carried out 
(Cochran–Mantel–Haenszel test stratified by study center).
Median changes in prolactin values from baseline to LOCF 
were summarized. Descriptive summaries of the Simpson–
Angus scale and the Barnes Akathisia scale were presented. 
Changes from baseline to end of study across treatment 
groups comparing the Simpson–Angus scale total score 
and the global clinical assessment of akathisia based on the 
Barnes Akathisia scale (Cochran–Mantel–Haenszel stratified 
by center) used the ANCOVA (with treatment group and 
study center as factors, and the baseline score as a covariate). 
Changes from screening to end of study in serum prolactin 
were analyzed using ANCOVA with treatment, study center, 
and gender of subject fitted as factors, and screening serum 
prolactin value as a covariate. Physical examination findings, 
vital signs, electrocardiographic parameters, including QTc 
intervals, were reviewed for all patients.
Results
Demographic and clinical characteristics 
of subjects
In total, 253 subjects were screened for entry into this study, 242 
were randomly assigned to treatment and 239 received treatment 
(Table 2). One hundred eighteen subjects and 121 subjects were 
assigned to receive ziprasidone and risperidone, respectively, 
and 97 (82%) and 111 (92%) completed the study, respectively. 
The subjects’ demographic and baseline clinical characteristics 
are summarized in Table 3. All subjects were Asian, with a 
primary diagnosis of schizophrenia (mean duration, range: 
6.4 years, 0.0–38.0 years and 5.3 years, 0.0–36.6 years for the 
ziprasidone and risperidone groups, respectively). Treatment 
groups were comparable for all baseline characteristics.
Dosing
This was a flexible-dose study in which the investigators were 
allowed to assign doses according to clinical judgment within 
the permissible range. At the end of treatment or at early 
termination, the proportion of subjects on the highest dose 
was comparable between the groups, ie, 21% for ziprasidone 
and 23% for risperidone. However, the proportion of subjects 
receiving the low and medium doses was different between 
treatment groups: low dose, 17% ziprasidone; 5% risperidone: 
medium dose, 62% ziprasidone; 72% risperidone. The mean 
daily prescribed dose by week is detailed in Table 4. The mean 
dosage received in the ziprasidone and risperidone groups was 
118.5 mg (SD = 18.1) and 3.8 mg (SD = 0.8), respectively.
Eighty-two (69.5%) ziprasidone-treated and 79 (65.3%) 
risperidone-treated subjects received clonazepam during the 
study. Sixty-two (52.5%) ziprasidone-treated and 56 (46.3%) 
risperidone-treated subjects received trihexyphenidyl during 
the study. While the study protocol permitted anticholinergic 
administration only as deemed clinically necessary, an 
earlier study had documented the need for prophylactic 
antiparkinsonian medication concomitant with neuroleptics 
to manage severe extrapyramidal symptoms.21
Efficacy
Primary efficacy endpoint
The extent of improvement (reduction) from baseline in 
PANSS total score was statistically significant and comparable 
Table 2 subject disposition
Screened n = 253
Assigned to treatment n = 242
Ziprasidone Risperidone
Treated, n (%) 118 (100) 121 (100)
completed, n (%) 97 (82) 111 (92)
Discontinued, n (%) 21 (18) 10 (8)
Analyzed for efficacy, n (%)
iTT population 118 (100) 121 (100)
evaluable population 96 (81) 111 (92)
Discontinuations, n 21 10
related to study drug 18 7
Adverse events 8 2
Lack of efficacy 9 5
Laboratory abnormality 1 0
Unrelated to study drug 3 3
Abbreviation: iTT, intent-to-treat.
Table 3 Baseline subject demographic and clinical characteristics
Ziprasidone  
(n = 118)
Risperidone   
(n = 121)
gender, female, n (%) 58 (49) 62 (51)
Age, years, mean (sD) 34.7 (10.8) 34.8 (10.9)
Weight, kg, mean (sD) 63.5 (12.1) 61.2 (10.1)
height, cm, mean (sD) 165.4 (7.2) 165.9 (7.6)
Baseline PANss score
  Total 84.4 (13.6) 84.6 (13.2)
  Positive 23.8 (5.5) 23.3 (5.8)
  Negative 20.8 (7.6) 21.5 (6.8)
  general psychopathology 39.8 (7.6) 39.8 (8.3)
Baseline BPrsd score 46.5 (7.8) 45.8 (7.5)
Abbreviations: sD, standard deviation; PANss, Positive and Negative syndrome 
scale; BPrsd, Brief Psychiatric rating scale derived from 18 PANss items.
Table 4 Prescribed daily dose by week
Treatment Week
1 2 4 Last visit
Ziprasidone,  
mean (n)
116.4 (110) 122.3 (106) 122.0 (100) 121.7 (118)
risperidone,  
mean (n)
3.8 (114) 4.2 (114) 4.3 (113) 4.4 (121)Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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for both treatment groups (Figure 1). At week 6, the difference 
between treatment groups was found to be 1.5 (standard 
error [SE] 2.03; 95% CI: −2.5, 5.5). Ziprasidone was found 
to be noninferior to risperidone at week 6 for the evaluable 
population; improvement from baseline to week 6 in PANSS 
total score was −35.6 (95% CI: −38.6, −32.6) for ziprasidone 
and −37.1 (95% CI: −39.9, −34.4) for risperidone. The upper 
limit of the 95% CI was well within the specified 10 units. 
Noninferiority of ziprasidone over risperidone was confirmed 
by the intent-to-treat population results, ie, least squares mean 
4.4 (SE 2.46, 95% CI: −0.4, 9.3).
Secondary efficacy endpoints
Statistically significant changes from baseline were observed 
for both treatment groups on all PANSS subscales and BPRSd 
(Table 5). No statistically significant differences between 
ziprasidone and risperidone were observed, apart from the 
PANSS general psychopathology score. This difference was 
not supported when analyzed using rank generalized linear 
models, consistent with the non-normality observed for this 
endpoint (P = 0.081).
The responder rate increased over time and was comparable 
between treatment groups at each time point. At the LOCF 
endpoint, 76 (64.4%) ziprasidone-treated and 87 (71.9%) 
risperidone-treated subjects had achieved a response. The odds 
of achieving a response to treatment with ziprasidone were 
similar to achieving a response to risperidone (odds ratio 0.71; 
95% CI: 0.41, 1.24).
Scores on CGI-I and CGI-S were improved for both 
treatment groups. However, a significantly greater   improvement 
was observed in the risperidone group on the CGI-I scale at 
week 6 compared with the ziprasidone group (mean at week 
6: risperidone 2.2 [SD 1.15], ziprasidone 2.6 [SD 1.31], 
P = 0.039), with 66.1% of risperidone-treated subjects 
achieving a CGI-I score #2 at week 6 compared with 55.9% 
in the ziprasidone group (P = 0.115).
safety and tolerability
Weight gain
Risperidone was associated with significant weight gain 
($7%) in 18 (14.9%, 95% CI: 9.06, 22.49) subjects, whereas 
only five (4.2%, 95% CI: 1.39, 9.61) ziprasidone subjects 
had significant weight gain at the end of the study compared 
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Figure 1 Mean change from baseline Positive and Negative syndrome scale total 
score (evaluable population).
Abbreviation: PANss, Positive and Negative syndrome scale.
Table 5 Ls mean change in PANss subscales and BPrsd scores 
(iTT population)
Change from baseline to week 6 (LOCF)
LS mean (SE) 95% CI P value
PANss positive
  Ziprasidone −10.2 (0.58) −11.3 to −9.0 ,0.001
  risperidone −11.5 (0.57) −12.6 to −10.3 ,0.001
  Difference between  
  treatment groups
1.3 (0.80) −0.3 to 2.9 0.105
PANss negative
  Ziprasidone −7.0 (0.53) −8.1 to −6.0 ,0.001
  risperidone −7.8 (0.52) −8.8 to −6.8 ,0.001
  Difference between  
  treatment groups
0.8 (0.73) −0.7 to 2.2 0.292
PANss general  
  psychopathology
    Ziprasidone −12.3 (0.79) −13.8 to −10.7 ,0.001
    risperidone −14.7 (0.78) −16.2 to −13.2 ,0.001
    Difference between  
    treatment groups
2.4 (1.09) 0.3 to 4.6 0.027
BPrsd
  Ziprasidone −16.1 (0.98) −18.0 to −14.1 ,0.001
  risperidone −18.4 (0.97) −20.3 to −16.5 ,0.001
  Difference between  
  treatment groups
2.3 (1.36) −0.4 to 5.0 0.088
Abbreviations: Ls, least squares; PANss, Positive and Negative syndrome scale; 
BPrsd, Brief Psychiatric rating scale derived from 18 PANss items; iTT, intent-to-
treat; LOCF, last observation carried forward; CI, confidence interval.
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Figure 2 Proportion of subjects with a $7% gain in body weight from baseline 
(safety population). 
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with baseline (Figure 2). No change was observed in median 
fasting glucose levels from baseline to last observation for 
both ziprasidone and risperidone groups (5 mg/dL).
serum prolactin
While serum prolactin levels increased from screening 
to week 6 in the risperidone group, mean prolactin levels 
decreased slightly in the ziprasidone group (Figure 3). 
A greater proportion of subjects in the risperidone group 
had significant prolactin abnormalities compared to the 
ziprasidone group. Among men treated with risperidone, 
all 16 subjects (100%) who were normal at baseline and 
28 of 29 (96.6%) subjects who were abnormal at baseline 
were reported to have abnormal serum prolactin levels. 
The corresponding values for ziprasidone-treated men were 
nine of 21 (42.9%) and 15 of 25 (60.0%), respectively. Among 
women treated with risperidone, the corresponding values 
were 13 of 13 (100%) and 38 of 39 (97.4%), respectively, 
compared with 9 of 15 (60.0%) and 23 of 37 (62.2%), 
respectively for ziprasidone-treated women.
Movement disorders
Ziprasidone and risperidone were comparable for change 
from baseline in both movement disorder scales. At week 6, 
Simpson–Angus scale scores were slightly increased compared 
with baseline in both groups. The least squares mean change 
from baseline was 0.9 (95% CI: 0.4, 1.4) in the ziprasidone 
group and 0.5 (95% CI: 0.0, 1.0) in the risperidone group 
(treatment difference 0.4, 95% CI: −0.3, 1.1). The majority 
of subjects did not experience worsening of symptoms 
(compared with baseline) on the Barnes Akathisia scale, and 
83% and 88% of subjects in the ziprasidone and risperidone 
groups, respectively, improved or experienced no change in 
symptoms.
Adverse events
In total, 94 (79.7%) ziprasidone-treated subjects and 86 
(71.1%) risperidone-treated subjects experienced 198 and 
152 treatment-related adverse events, respectively. The body 
system most affected by study treatment was the nervous 
system, with 70 (59%) and 51 (42%) subjects reporting 
adverse events in the ziprasidone and risperidone groups, 
respectively. Treatment-related adverse events ($5% in any 
treatment group) are summarized in Table 6. The majority 
of adverse events were mild or moderate in severity. Three 
adverse events in each group were reported as severe: 
the ziprasidone group reported severe akathisia (n = 43, 
36.4%), neuroleptic malignant syndrome (n = 1, 0.9%), 
and somnolence (n = 11, 9.3%); the risperidone group 
reported severe akathisia (n = 2) and insomnia (n = 1). Eight 
subjects (6.8%) in the ziprasidone group and two subjects 
(1.7%) in the risperidone group withdrew permanently 
from the study due to treatment-related adverse events. 
One additional subject discontinued from the ziprasidone 
group due to abnormal laboratory test results. This subject 
had normal baseline alanine aminotransferase (21 U/L) 
and aspartate aminotransferase (31 U/L) levels, but alanine 
aminotransferase (115 U/L) and aspartate aminotransferase 
(57 U/L) increased on day 29.
One subject had a serious adverse event during treatment 
with ziprasidone. The physician reported that the subject 
suffered from severe neuroleptic malignant syndrome 
characterized by fever (39.4°C) and significant extrapyramidal 
symptoms, along with the consciousness disorder. Treatment 
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Figure  3  Mean  change  in  serum  prolactin  from  screening  to  week  6  (safety 
population). 
Abbreviations: ci, confidence interval; LS, least squares.
Table 6 Treatment-related, treatment-emergent adverse events 
occurring in $5% of subjects
Ziprasidone  
(n = 118)  
n (%)
Risperidone   
(n = 121)  
n (%)
Akathisia 43 (36.4) 29 (24.0)
extrapyramidal disorder 26 (22.0)  20 (16.5)
constipation 17 (14.4) 19 (15.7)
somnolence 11 (9.3) 2 (1.7)
Dystonia 8 (6.8) 6 (5.0)
ALT increased 7 (5.9) 14 (11.6)
AsT increased 7 (5.9) 6 (5.0)
Dizziness 6 (5.1) 8 (6.6)
Palpitations 6 (5.1) 6 (5.0)
sinus tachycardia 6 (5.1) 2 (1.7) 
Abbreviations: ALT, alanine aminotransferase; AsT, aspartate aminotransferase.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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was halted, and the subject recovered after being permanently 
discontinued from the study, which suggested that this 
adverse event was induced by ziprasidone.
Vital signs
Slight decreases in resting pulse rate were observed 
(ziprasidone, −1.00 beats/minute; risperidone, −4.00 beats/
minute). In both treatment groups, the median measured 
resting systolic and diastolic blood pressure was 120 mmHg 
and 75 mmHg, respectively.
electrocardiographic parameters
The majority of subjects (n = 117 in both treatment groups) 
had an electrocardiogram performed at screening and had 
electrocardiographic results within normal limits (ziprasidone 
n = 89 and risperidone n = 97). The mean (SD) values of 
QTc (Bazett correction) at baseline and last observation 
for the ziprasidone group were 403.6 (24.52) msec and 
403.6 (32.26) msec and for the risperidone group were 
402.3 (26.71) msec, and 399.9 (25.21) msec, respectively. 
Accordingly, the QTc change (SD) from baseline to last 
observation for ziprasidone and risperidone was 0.00 (33.1) 
sec and −2.4 (27.8) msec, respectively. One subject on 
ziprasidone had an increased QTc interval postbaseline 
from 360 msec at baseline to 511 msec, but showed no 
corresponding clinical manifestations.
Discussion
In this Chinese sample, ziprasidone was determined to be as 
effective as (noninferior to) risperidone, as determined by the 
primary efficacy measure, ie, change in PANSS total score from 
baseline to week 6. Similar improvements from baseline to week 
6 on PANSS positive and negative subscales, BPRSd, PANSS 
responder rate, and CGI-S, were observed for ziprasidone and 
risperidone. The statistically significant treatment difference 
in the PANSS general psychopathology subscale was not 
supported when the data were analyzed using a prespecified 
rank generalized linear model. However, a statistically 
significant treatment difference in favor of risperidone was 
observed for the CGI-I at week 6. Furthermore, ziprasidone 
demonstrated a low propensity for weight gain and had neutral 
effects on prolactin levels, compared with risperidone.
One ziprasidone-treated subject had a QTc value 
of $500 msec, but showed no corresponding clinical 
manifestations. QTc prolongation in ziprasidone-treated 
subjects occurs rarely. The safety profile of ziprasidone 
indicates that, as of February 2000, 2 of 3095 (0.064%)   
subjects  receiving  ziprasidone  demonstrated  QTc 
values $500 msec compared with one of 440 (2.3%) subjects 
receiving placebo.22 Furthermore, of the ziprasidone-treated 
subjects in the safety database, neither case suggested a role 
for ziprasidone.
Because the majority of clinical studies of atypical 
antipsychotics have been conducted in largely Western 
populations, randomized, double-blind studies of atypical 
antipsychotics in Asian populations are rare. In a 12-week, 
randomized, double-blind study in Chinese inpatients, 
treatment with risperidone resulted in a significantly greater 
reduction in PANSS total score compared with haloperidol, 
with fewer side effects.23 While baseline PANSS total scores 
in the present study (ziprasidone group, 84.4; risperidone 
group, 84.6) were similar to those for the aforementioned 
study (risperidone group, 82.4; haloperidol group, 79.3), 
a greater reduction in PANSS total score was observed 
in the present study for risperidone-treated subjects. In a 
24-week, randomized, double-blind, multicenter study of 
olanzapine versus haloperidol in Asian outpatients, subjects 
treated with both medications improved significantly within 
eight weeks.24 Changes in PANSS total scores from baseline 
to week 8 are similar to the changes observed in the present 
study. In a four-week, double-blind, randomized, parallel 
study of aripiprazole and risperidone in Chinese inpatients, 
both treatment groups demonstrated improvement from 
baseline in PANSS total, PANSS positive, and PANSS nega-
tive scores, as well as CGI-S scores at the study endpoint.25 
Baseline scores were similar to the present study, and changes 
from baseline PANSS scores to week 4 were comparable 
(change from baseline to week 4 [intent-to-treat]: present 
study, ziprasidone, −16.6; risperidone, −19.7 versus Chan 
et al25 aripiprazole −19.6; risperidone, −21.1). In addition 
to the comparable efficacy of ziprasidone and risperidone 
observed in the present study, another comparative study of 
ziprasidone and risperidone in combination with adjunctive 
clozapine for schizophrenia also showed similar efficacy for 
these two atypical antipsychotics.26,27
Baseline psychopathology scores in the present study 
(PANSS: ziprasidone, 84.4, risperidone, 84.6; BPRS: 
ziprasidone, 46.5, risperidone 45.8) appear to be slightly 
lower than scores reported for short-term Western studies 
of ziprasidone in subjects with schizophrenia. Future 
studies will be required to determine whether the severity of 
psychopathology at baseline is consistently lower in Chinese 
populations, or if this finding is unique to this study. Daniel 
et al reported mean baseline PANSS total scores between Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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95.8 and 98.2, PANSS negative subscale scores between 
24.3 and 25.4, and BPRS total scores between 55.0 and 56.5.3 
Simpson et al reported mean baseline PANSS total scores, 
negative subscale scores, and positive subscale scores of 90, 
22.2, and 23.3, respectively, and BPRS total score of 51.5.28 
Keck et al reported mean baseline BPRS total scores ranging 
between 36.5 and 37.0.2 Addington et al reported mean 
baseline PANSS total scores of 93.8 and 97.6 for ziprasidone 
and risperidone groups, respectively.29 It should be noted 
that baseline psychopathology scores in CATIE (Clinical 
Antipsychotic Trials of Intervention Effectiveness) were 
lower, ranging from 74.3 to 76.4. However, these results may 
not be comparable due to differences in study design.
Of the aforementioned studies, the design of the Addington 
et al study, an eight-week, double-blind, randomized, 
multicenter comparison of ziprasidone and risperidone 
in the treatment of acute exacerbation of schizophrenia 
or schizoaffective disorder, is most similar to the present 
study.29 While baseline PANSS total scores in the Addington 
study were higher than in our study, changes from baseline 
to study endpoint were smaller (in the Addington et al study, 
ziprasidone, −25.8; risperidone, −27.3). Responder rates, as 
defined by a $50% reduction from baseline PANSS total 
score, were higher in the present study. The total mean 
prescribed daily dose of ziprasidone was similar between 
studies; the total mean prescribed dose of risperidone was 
higher in the Addington study (7.39 mg/day overall versus 
3.7 mg/day in the present study). However, this study has a few 
limitations, including the relatively short observational period, 
absence of a placebo group, and lack of scales evaluating 
depressive symptoms.
In our study, ziprasidone had neutral effects on mean 
prolactin levels, but the use of risperidone was associated 
with significant increases in mean prolactin levels from 
baseline in both men and women. The low rates of prolactin 
elevation with ziprasidone treatment compared with other 
atypicals is thought to be due to the mechanism of action 
of the drug (offsetting effects on 5-HT1A and 5-HT2A 
receptors).30 Clinically significant elevations in prolactin 
were more common in risperidone-treated subjects than in 
ziprasidone-treated subjects in the Addington et al study 
as well.
The baseline weight of subjects in the present study is 
considerably lower than baseline weights reported in Western 
studies. Here, baseline weights in the ziprasidone and 
risperidone groups were 63.5 kg and 61.2 kg, respectively. 
Mean baseline weights in several short-term Western trials 
of ziprasidone in schizophrenia ranged from 77.9 kg to 
87.1 kg in men, and from 64.5 to 80.7 kg in women.2,3,28 
A difference in height may partially account for differences 
in baseline weight between this study population and Western 
study populations; in the Simpson study,28 mean height was 
171.9 cm versus 165.4 cm and 165.9 cm for ziprasidone 
and risperidone, respectively, in the present study. Despite 
these baseline differences in weight between the present 
study population and the Western study populations, the 
incidence of weight gain $7% of baseline body weight in 
the present study was similar to Western studies (present 
study, 15% of risperidone-treated subjects versus 4% of 
ziprasidone-treated subjects; Addington et al study, 16.0% 
of risperidone-treated subjects versus 8.2% of ziprasidone-
treated subjects; CATIE, 14.0% of risperidone-treated 
subjects versus 4.0% of ziprasidone-treated subjects).29,31 
Other metabolic parameters, such as lipid metabolism 
and heart rate variability, were not measured in this study, 
although resting blood pressure and fasting glucose levels 
were similar between the treatment groups. Rates of 
movement disorders, as measured by the Barnes Akathisia 
scale, were similar between the studies.
In this Chinese sample, we found that ziprasidone 
was as effective (noninferior) as risperidone for treating 
acute exacerbation of schizophrenia, as determined by the 
PANSS total score. The safety profiles of these two drugs 
were comparable. Overall, ziprasidone was safe and well 
tolerated in this Chinese population. Few randomized 
placebo-controlled studies of atypical antipsychotics in 
Chinese subjects with schizophrenia exist, because the 
majority of studies are conducted in Western populations. 
The Chinese subjects in the present study had slightly lower 
baseline psychopathology scores than what has been reported 
for several Western studies, but experienced substantial 
improvement following treatment. Chinese subjects had 
lower weight at baseline than subjects in Western studies. 
Despite baseline differences, Chinese subjects treated with 
risperidone experienced weight gain and prolactin elevation, 
as is often seen in Western studies. By contrast, ziprasidone 
demonstrated lower liability for weight gain and favorable 
effects on prolactin levels. Here, we have established that 
ziprasidone is an appropriate treatment option for Chinese 
subjects with schizophrenia.
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